MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines

RXDX-106 is a potent and selective type II pseudo-irreversible (slow off-rate) inhibitor of TYRO3, AXL, MER and c-MET. MER tyrosine kinase (MerTK) is expressed in a variety of malignancies, including gastric cancer (GC). The oncogenic potential of MerTK is supported by various lines of evidence. Fir...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Kim, Jung Eun, Kim, Youjin, Li, Gary, Kim, Seung Tae, Kim, Kyung, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Lee, Hyuk, Sohn, Tae Sung, Kim, Kyoung-Mee, Kang, Won Ki, Lee, Jeeyun
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739674/
https://ncbi.nlm.nih.gov/pubmed/29285287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22394
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items